Multi-functional technology adds to company’s bioavailability enhancement and modified release suites
Morristown, N.J., October 7, 2014 – Capsugel announced today the broad commercial availability of its proprietary lipid multiparticulate (LMP) technology. Capsugel’s LMP technology is an innovative drug-delivery platform with multiple applications – including bioavailability enhancement, taste-masking and modified release – for both pharmaceutical and health and nutrition (H&N) products. The company’s LMP technology is based on its melt-spray congeal (MSC) processing and combines the benefits of lipid-based formulations (LBF) with the functionality of a multiparticulate dosage form in one unique offering.
"With our LMP technology, Capsugel is again employing its advanced science and engineering to provide clients with innovative options to achieve their target product profiles and commercial objectives,” said Keith Hutchison, Ph.D., Senior Vice President, Research & Development, Capsugel. “LMP technology already has a commercialized pharmaceutical product, and we have developed several product applications in the H&N marketplace. Given its performance and flexibility, we expect LMPs to become the right solution to address many client project challenges.”
The expansion of Capsugel’s LMP technology enhances the company’s ability to bring value to healthcare customers around the world by helping them design, develop and manufacture new compounds – and improve existing ones. LMP technology complements Capsugel’s unparalleled array of bioavailability enhancement technologies, including LBF options in either liquid-filled hard capsules or soft gels for oral delivery. It also adds to the company’s breadth and depth of multiparticulate options offered to clients, which includes fluid-bed-layered, extrusion and mini-tablet approaches. Several client projects are currently evaluating LMP as a formulation option.
“Bringing LMP technology to market has required the successful integration of our capabilities in process development, formulation and specialized production equipment,” added Amit Patel, President, Dosage Form Solutions, Capsugel. “Our premier range of technologies and specialized manufacturing allows clients to have one partner throughout the product development cycle – from design to commercial manufacture of finished dosage forms – offering accelerated speed to market, while reducing overall costs and risks to their program.”
MSC processing for LMP production is currently available at Capsugel’s manufacturing site in Bend, Ore., and a commercial-scale facility with MSC processing and capsule-filling capability was recently installed at its location in Greenwood, S.C. The company is also continuing to innovate and evolve its global manufacturing processes and capabilities for LMP to extend the reach and applicability for its global customer base.
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business unit offers customers the broadest portfolio of gelatin, vegetarian and other specialized capsule technologies. Capsugel’s Dosage Form Solutions business unit solves customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. Capsugel Dosage Form Solutions accelerates and improves product development through an array of proprietary technologies including lipids and liquids, spray-dried dispersions, hot-melt extrusions, and through specialized manufacturing including FDA/MHRA-accredited finished dosage sites that can handle highly potent, controlled substance, hormonal and oncology compounds. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit www.capsugel.com.